Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 301 - 350 out of 9,408

Document Document Title
WO/2011/059021A1
Disclosed is a compound represented by formula (1) or a pharmacologically acceptable salt thereof. (In the formula, A represents a group that is represented by formula (A-1); R1a and R1b may be the same or different and each independentl...  
WO/2011/059416A1
The invention relates to pharmacology, medicine, livestock breeding and poultry farming, and is directed towards producing agents and methods which can be used for prophylactic aims in order to reduce the risk of morbidity caused by nega...  
WO/2011/059733A3
The present invention provides lipoic acid or derivatives thereof for use in graft stabilization of fat grafts. Mixing of lipoic acid or a derivative thereof with adipocytes or adipose tissue to be transplanted into a subject leads to mo...  
WO/2011/058773A1
Disclosed is a composition which is capable of stably containing a carotenoid for a long period of time. The composition is characterized by containing (A) a carotenoid, (B) a middle chain saturated fatty acid triglyceride and (C) tocotr...  
WO/2011/056234A1
The present invention relates to methods and medicaments useful for treatment of radiation-induced disorders by administering anti-CTGF agents, particularly anti-CTGF antibodies. Methods and medicaments for pre-treating individuals havin...  
WO/2011/055869A1
The present invention relates to a therapeutic agent for diabetic complications and a treatment method for diabetic complications using the same, and more specifically, to an agent for prevention and treatment of diabetic complications c...  
WO/2011/050152A3
Methods and compositions for site-specific modification of amino acids, peptides, polypeptides and proteins are disclosed.  
WO/2011/049484A1
The invention relates to the chemico-pharmaceutical industry, specifically to the production of an antioxidant. The antioxidant comprises the following ingredients: flower pollen, dihydroquercetin, vitamin С, vitamin E, honeybee royal j...  
WO/2011/050152A2
Methods and compositions for site-specific modification of amino acids, peptides, polypeptides and proteins are disclosed.  
WO/2011/046199A1
Provided are a component, which not only has an ability to reduce oxidized coenzyme Q10 and an ability to stabilize reduced coenzyme Q10 but also contains nutrients and has a good taste and broad utility, and a method for using the same....  
WO/2011/044701A1
Described herein are isolated polypeptides having phosphatase and tensin homolog (PTEN) inhibitory activity, vectors and cells for the expression thereof and methods for their use in treating a diseases associated with cytotoxic stress, ...  
WO/2011/045934A1
Provided are a component, which not only has an ability to reduce oxidized coenzyme Q10 and an ability to stabilize reduced coenzyme Q10 but also contains nutrients and has a good taste and broad utility, and a method for using the same....  
WO/2011/037467A1
The invention relates to Atazanavir for use as a medicament for preventing, treating and/or delaying an inflammation-mediated or -associated disease and/or a disease wherein oxidative stress occurs.  
WO/2011/038385A2
Sulfur-containing ligands and methods of their utilization for binding metals and/or main group elements and removing them from fluids, solids, gases and/or tissues are disclosed. The ligands are of the general structure (A): or structur...  
WO/2011/038385A9
Sulfur-containing ligands and methods of their utilization for binding metals and/or main group elements and removing them from fluids, solids, gases and/or tissues are disclosed. The ligands are of the general structure (A): or structur...  
WO/2011/037099A1
The purpose of the present invention is to further improve the hangover symptom-relieving effect of a composition comprising a Curcuma longa extract. More specifically, the purpose of the invention is to provide a composition by which sp...  
WO/2011/038385A3
Sulfur-containing ligands and methods of their utilization for binding metals and/or main group elements and removing them from fluids, solids, gases and/or tissues are disclosed. The ligands are of the general structure (A): or structur...  
WO/2011/033717A1
Disclosed are a goya (Momordica charantia L. var. pavel Crantz) koji composition, which is obtained by fermenting goya, that is an inexpensive and easily available material, with a koji mold, has elevated antioxidative and ACE-inhibitory...  
WO/2011/028673A2
Disclosed herein is a composition for delaying cellular senescence comprising from about 0.01 wt% to about (5) wt% of Hexapeptide-11(Phe-Val-Ala-Pro-Phe-Pro), based on the total weight of the composition, and a dermatologically-acceptabl...  
WO/2011/023653A1
The invention relates to a method for treating an overdosing with active substance dabigatran etexilate of formula I optionally in the form of the pharmaceutically acceptable salts thereof, comprising the administration of an effective a...  
WO/2011/025019A1
Disclosed is a lactic acid bacterium that is suitable for foods, beverages, and medicines, induces thioredoxin, and is capable of preventing/and or ameliorating a variety of biological damage resulting from oxidative stress. Also disclos...  
WO/2011/021218A3
An improved process for preparing 4-[3, 5-bis (2-hydroxyphenyl)-l, 2, 4-tπazol-l -yl] benzoic acid of formula-1 and a process for its purification are provided The preparation process comprises reacting salicylic acid with salicylamide ...  
WO/2011/018885A1
Disclosed are: a skin whitening agent which has an excellent skin whitening activity and can exhibit an excellent effect on the reduction in pigment deposition after sunburn, pigmented spots, freckles, chloasma or the like and the whiten...  
WO/2011/016459A1
Disclosed is a compound which has serotonin 5-HT2C receptor activating activity. Specifically disclosed is a compound represented by formula (I) or a salt thereof. (In the formula, the symbols are as defined in the description.)  
WO/2011/008800A1
The invention encompasses pet food composition that delivers a slow, sustained-release amount of lipoic acid or a salt thereof when fed orally to a companion animal. The invention also encompasses methods of manufacture and use of the co...  
WO/2011/002070A1
A pharmaceutical composition for treating iron overload disorders or diseases on which the reduction in an iron concentration is effective, which comprises a protein comprising GDF7 or a vector carrying a nucleic acid encoding the protei...  
WO/2010/144055A1
The invention relates to compounds represented by the general formula (I): and pharmaceutically acceptable salts thereof, wherein n is an integer from 1 to 5; p is an integer from 0 to 4; R1 is selected from the group consisting of a hyd...  
WO/2010/143006A1
Use of orally bioavailable iron chelators for the manufacturing of a pharmaceutical composition for the treatment of an inflammatory bowel disease. Useful such chelators include deferiprone and deferasirox.  
WO/2010/142041A1
The present invention relates to novel serine rich peptides capable of exhibiting antioxidative properties and that can be used to protect a cell, tissues, organs or a multi-cellular organism, such as animals, against oxidative stress. I...  
WO/2010/140271A1
Disclosed is a substance which can potentiate the power of α brain waves produced from the cerebrum of a human to exhibit a relaxing activity, an concentration-enhancing activity and an anti-stress activity. Specifically disclosed is a ...  
WO/2010/132822A1
A nutritional composition for reducing oxidative damage and lipid peroxidation in humans, while allowing for the oxidative reactions necessary to sustain vital biological functions. The nutritional compositions comprise adaptogens compri...  
WO/2010/132024A1
A carotenoid and a terpenoid in therapeutically-effective amounts is disclosed such that, upon ingestion in one preparation, or in two separated preparations, simultaneous or sequentially, and upon metabolism, the activity of natural kil...  
WO/2010/125202A1
The present invention is in the fields of medicine, public health, immunology, molecular biology and virology. The invention provides compositions, vaccine compositions and pharmaceutical compositions for the treatment, amelioration and ...  
WO/2010/123569A3
Disclosed are synthetic nanocarrier compositions, and related methods, for treating diseases in which generating a Th1 -biased immune response is desirable. In an aspect, the invention relates to a composition for treatment of a conditio...  
WO/2010/121177A3
Described herein are pharmaceutical compositions and medicaments, and methods of using such pharmaceutical compositions and medicaments in the treatment of inflammation and cancer.  
WO/2010/121177A2
Described herein are pharmaceutical compositions and medicaments, and methods of using such pharmaceutical compositions and medicaments in the treatment of inflammation and cancer.  
WO/2010/120368A2
Radiopharmaceutical compositions, and related methods, useful for medical imaging are provided. The radiopharmaceutical compositions include one or more radiopharmaceutical compounds, together with a stabilizer comprising ascorbic acid, ...  
WO/2010/120368A3
Radiopharmaceutical compositions, and related methods, useful for medical imaging are provided. The radiopharmaceutical compositions include one or more radiopharmaceutical compounds, together with a stabilizer comprising ascorbic acid, ...  
WO/2010/112071A1
The present invention relates to a pharmaceutical or dietary composition containing Astaxanthin and several antioxidants with sunscreen effect and being characterized by oral administration. The present invention relates to a formulation...  
WO/2010/112510A1
The present invention relates generally to the field of hesperetin bioavailability. One embodiment of the present invention is directed at a composition that allows to increase the bioavailability of hesperetin and consequently to maximi...  
WO/2010/112113A1
The present invention refers to a pharmaceutical composition comprising uric acid and citicoline for the neuroprotective treatment of patients with ictus.  
WO/2010/113900A1
Disclosed is a production method for ubiquinone powder for use in preparations that involves a process (1) for obtaining compressed fragments by compression molding ubiquinone crystal powder at a linear molding pressure of 0.6-2.5 ton/cm...  
WO2010110334A1
Disclosed is a method for improving the solubility of myricitrin in water. Also disclosed is a readily water-soluble myricitrin composition which is improved in the solubility in water by the method. Specifically disclosed is a method fo...  
WO2010110328A1
Disclosed is a method for improving the solubility of isoquercitrin in water. Also disclosed is a readily water-soluble isoquercitrin composition which is improved in the solubility in water by the method. Specifically disclosed is a met...  
WO/2010/104147A1
Disclosed is an antioxidant agent which can exhibit a higher antioxidative ability than those of existing antioxidant peptides. The antioxidant agent comprises mimosine or a mimosine-containing peptide. The mimosine-containing peptide is...  
WO/2010/104370A1
The present invention discloses an extract having neuroprotective property prepared from a plant of the family Palmae, which is capable in preserving neurons against damage caused by oxidation, ageing and/or nitric oxide deficiency. Also...  
WO/2010/098442A1
Disclosed is a carbon monoxide removal agent that can be easily administered to a patient by injection or orally. The carbon monoxide removal agent contains an inclusion complex, in which a cyclodextrin dimer represented by chemical form...  
WO/2010/096925A1
The invention relates to methods, materials and compositions for administering homotaurine in a subject, preferably a human subject. The invention encompasses compositions and materials enriched/supplemented in homotaurine. Preferred com...  
WO/2010/092419A1
The invention concerns a novel treatment multiple sclerosis, based on induced anaemia, followed by administration of an erythropoiesis-stimulating agent (ESA). In a preferred embodiment, the ESA is darbopoietin alpha, CERA or Hematide. T...  
WO/2010/093787A3
Nitric oxide synthase (NOS) inhibitor compounds comprising bi-terminal aromatic ring moieties, and related methods of NOS inhibition.  

Matches 301 - 350 out of 9,408